Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles

• References

• 1 Visser LE, van Schaik RH, van Vliet M. et al The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.. Thromb Haemost 2004; 92: 61-6.
• 2 Schalekamp T, van Geest-Daalderop JHH, de Vries-Goldschmeding H. et al Acenocoumarol stabilization is delayed in CYP2C9*3 carriers.. Clin Pharmacol Ther 2004; 75: 394-402.
• 3 Morin S, Bodin L, Loriot M-A. et al Pharmacogenetics of acenocoumarol pharmacodynamics.. Clin Pharmacol Ther 2004; 75: 403-14.
• 4 Takahashi H, Wilkinson GR, Padrini R. et al CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.. Clin Pharmacol Ther 2004; 75: 376-80.